Abstract
Isocitrate dehydrogenase mutational status defines distinct biologic behavior and clinical outcomes in low-grade gliomas. We sought to determine magnetic resonance imaging characteristics associated with isocitrate dehydrogenase mutational status to evaluate the predictive roles of magnetic resonance imaging features in isocitrate dehydrogenase mutational status and therefore their potential impact on the determination of clinical target volume in radiotherapy. Forty-eight isocitrate dehydrogenase-mutant and 28 isocitrate dehydrogenase-wild-type low-grade gliomas were studied. Isocitrate dehydrogenase mutation was related to more frequency of cortical involvement compared to isocitrate dehydrogenase-wild-type group (34/46 vs 6/24, P = .0001). Peritumoral edema was less frequent in isocitrate dehydrogenase-mutant tumors (32.6% vs 58.3% for isocitrate dehydrogenase-wild-type tumors, P = .0381). Isocitrate dehydrogenase-wild-type tumors were more likely to have a nondefinable border, while isocitrate dehydrogenase-mutant tumors had well-defined borders (66.7% vs 39.1%, P = .0287). Only 8 (17.4%) of 46 of the isocitrate dehydrogenase-mutant tumors demonstrated marked enhancement, while this was 66.7% in isocitrate-wild-type tumors (P < .0001). Choline-creatinine ratio for isocitrate dehydrogenase-wild-type tumors was significantly higher than that for isocitrate dehydrogenase-mutant tumors. In conclusion, frontal location, well-defined border, cortical involvement, less peritumoral edema, lack of enhancement, and low choline-creatinine ratio were predictive for the definition of isocitrate dehydrogenase-mutant low-grade gliomas. Magnetic resonance imaging can provide an advantage in the detection of isocitrate dehydrogenase status indirectly and indicate the need to explore new design for treatment planning in gliomas. Choline-creatinine ratio in magnetic resonance spectroscopy could be a potential more reasonable reference for the new design of delineation of target volume in low-grade gliomas.